Omnio is targeting hard-to-heal diabetic foot ulcers, which its pages describe as a major source of suffering, mobility loss and amputation risk, with advanced cases costing healthcare systems an estimated €50,000 per wound episode. Its recombinant plasminogen is intended to address the biology of stalled healing and infection rather than merely manage symptoms, and the latest €2.9 million round is funding GMP manufacturing and toxicology work ahead of planned Phase I/IIa patient studies.